Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8327094 | 0.86 | TSHR (0.59) | SMN1; SMN2MAP2K1FFAR1CYP1A2CYP2C19 | |
| SCHEMBL23120213 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP1A2CYP2C19RAB9AHPGD | |
| SCHEMBL29663590 | 0.86 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP1A2CYP2C19RAB9AHPGD | |
| SCHEMBL29965698 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2MAP2K1FFAR1CYP1A2CYP2C19 | |
| SCHEMBL20679600 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2MAP2K1FFAR1CYP1A2CYP2C19 | |
| SCHEMBL7930522 | 0.85 | MAP2K1 (0.56) | SMN1; SMN2MAP2K1FFAR1CYP1A2CYP2C19 | |
| SCHEMBL24499540 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP1A2CYP2C19RAB9AHPGD | |
| SCHEMBL5866568 | 0.83 | ALDH1A1 (0.52) | SMN1; SMN2CYP1A2CYP2C19RAB9AHTT | |
| SCHEMBL18516263 | 0.82 | MET (0.55) | SMN1; SMN2MAP2K1FFAR1TSHRRAB9A | |
| SCHEMBL5621845 | 0.82 | CYP1A2 (0.51) | SMN1; SMN2MAP2K1FFAR1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034727-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. | 2024-02-01 | — | — | US | disclosed |
| CN-116963733-A | Imidazole compounds as ENPP1 inhibitors | 斯汀格瑞治疗股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4255425-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022119928-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022119928-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | Stingray Therapeutics, Inc. (US) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034727-A1 | IMIDAZOLE COMPOUNDS AS INHIBITORS OF ENPP1 | ENPP1, PPP1R1B, PPM1B | SMN1; SMN2 865/4885MAP2K1 2806/4885FFAR1 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.